Background: Chronic hypoxia induces lung vascular remodeling, which results in pulmonary hypertension. Vascular remodeling is associated with collagenolysis and activation of matrix metalloproteinases (MMPs). One of the possible sources of MMPs in hypoxic lung are mast cells. Objective: The role of lung mast cell collagenolytic activity in hypoxic pulmonary hypertension was tested by the inhibitor of mast cell degranulation disodium cromoglycate (DSCG). Methods: Rats were treated with DSCG in an early or later phase of isobaric hypoxia. Control groups were exposed to hypoxia only or to normoxia. Lung hemodynamics, muscularization and collagen metabolism in the walls of peripheral pulmonary vessels in the lungs were measured. Results: DSCG applied at an early phase of exposure to hypoxia reduced the development of pulmonary hypertension, inhibited muscularization in peripheral pulmonary arteries and decreased the amount of collagen cleavage fragments in prealveolar vessels. Conclusions: Mast cell degranulation plays a role in the initiation of hypoxic pulmonary vascular remodeling.

Keywords:
Hypoxic pulmonary hypertension, Disodium cromoglycate, Mast cell, Pulmonary vascular remodeling, Matrix metalloproteinases
1.
Novotná J, Herget J: Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res 2002;51:323–334.
2.
Novotná J, Herget J: Exposure to chronic hypoxia induces qualitative changes of collagen in the walls of peripheral pulmonary arteries. Life Sci 1998;62:1–12.
3.
Herget J, Wilhelm J, Novotná J, Eckhardt A, Vytášek R, Mrázková L, Ošcádal M: A possible role of oxidant tissue injury in the development of pulmonary hypertension. Phys Res 2000;49:493–501.
4.
Herget J, Novotná J, Bíbová J, Povýšilová V, Vaňková M, Hampl V: Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2003;285:L199–L208.
5.
Vajner L, Vytasek R, Lachmanova V, Uhlik J, Konradova V, Novotna J, Hampl V, Herget J: Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol 2006;87:383–391.
6.
Maxová H, Novotná J, Vajner L, Vízek M, Vytášek R, Herget J: Hypoxia increases synthesis of metalloproteinases in isolated rat lung mast cells. Phys Res 2002;51:69P.
7.
Hampl V, Herget J: Perinatal hypoxia increases hypoxic pulmonary vasoconstriction in adult rats recovering from chronic exposure to hypoxia. Am Rev Respir Dis 1990;142:619–624.
8.
Herget J, Paleček F: Pulmonary arterial blood pressure in closed chest rats. Changes after catecholamines, histamine and serotonin. Arch Int Pharmacodyn Ther 1972;198:107–117.
9.
Hampl V, Archer SL, Nelson DP, Weir EK: Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure. J Appl Physiol 1993;75:1748–1757.
10.
Herget J, Suggett AJ, Leach E, Barer GR: Resolution of pulmonary hypertension and other features induced by chronic hypoxia in rats during complete and intermittent normoxia. Thorax 1978;33:468–473.
11.
Wilhelm J, Vankova M, Maxova H, Siskova A: Hydrogen peroxide production by alveolar macrophages is increased and its concentration is elevated in the breath of rats exposed to hypoxia: relationship to lung lipid peroxidation. Physiol Res 2003;52:327–332.
12.
Novotná J, Bíbová J, Hampl V, Deyl Z, Herget J: Hyperoxia and recovery from hypoxia alter collagen in peripheral pulmonary arteries similarly. Physiol Res 2001;50:153–163.
13.
Gardi C, Martorana PA, Calzoni P, Cavara E, Marcolongo P, de Santi MM, van Even P, Lungarella G: Cardiac collagen changes during the development of right ventricular hypertrophy in tight-skin mice with emphysema. Exp Mol Pathol 1994;60:100–107.
14.
Nadziejko CE, Loud AV, Kikkawa Y: Effect of alveolar hypoxia on pulmonary mast cells in vivo. Am Rev Respir Dis 1989;140:743–748.
15.
Kay JM, Suyama KL, Keane PM: Mast cell stabilizing compound FPL 55618 reduces right ventricular hypertrophy and lung mast cell hyperplasia in chronically hypoxic rats. Experientia 1981;37:75–76.
16.
Mungall IPF: Hypoxia and lung mast cells: influence of disodium cromoglycate. Thorax 1976;31:94–100.
17.
Zhu YJ, Kradin R, Brandstetter RD, Staton G, Moss J, Hales CA: Hypoxic pulmonary hypertension in the mast cell-deficient mouse. J Appl Physiol 1983;54:680–686.
18.
Tucker A, McMurtry I, Alexander AF, Reeves JT, Grover RF: Lung mast cell density and distribution in chronically hypoxic animals. J Appl Physiol 1977;42:174–178.
19.
Matsuo N, Shimoda T, Matsuse H, Obase Y, Asai S, Kohno S: Effects of sodium cromoglycate on cytokine production following antigen stimulation of a passively sensitized human lung model. Ann Allergy Asthma Immunol 2000;84:72–78.
20.
Theoharides TC, Wang L, Pang X, Letourneau R, Culm KE, Basu S, Wang Y, Correia I: Cloning and cellular localization of the rat mast cell 78-kDa protein phosphorylated in response to the mast cell ‘stabilizer’ cromolyn. J Pharmacol Exp Ther 2000;294:810–821.
21.
Steiner DR, Gonzalez NC, Wood JG: Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol 2003;94:325–334.
22.
Hampl V, Herget J: Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000;80:1337–1384.
23.
Filley GF, Beckwitt HJ, Reeves JT, Mitchell RS: Chronic obstructive bronchopulmonary disease. 2. Oxygen transport in two clinical types. Am J Med 1968;44:26–38.
24.
Turato G, Zuin R, Saetta M: Pathogenesis and pathology of COPD. Respiration 2001;68:117–128.
25.
van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008;75:224–238.
26.
Rakusan K, Sarkar K, Turek Z, Wicker P: Mast cells in the rat heart during normal growth and in cardiac hypertrophy. Circ Res 1990;66:511–516.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.